Moderna and Immatics Join Forces in 2025 with $1.7 Billion Deal to Revolutionize Cancer Vaccines

Bill McColl brings over 25 years of expertise as a senior producer and writer across TV, radio, and digital platforms, leading teams that deliver impactful news coverage on major global stories.

Highlights

• Moderna collaborates with Germany's Immatics to pioneer innovative cancer vaccines and therapies.
• Immatics secures $120 million upfront, with total deal value potentially reaching $1.7 billion plus royalties.
• Partnership awaits approval from U.S. antitrust regulators.

In a landmark 2024 agreement, Moderna (MRNA) and German biotech firm Immatics have committed to jointly develop vaccines and treatments targeting cancer, utilizing the advanced mRNA technology that powered Moderna’s successful COVID-19 vaccines.

Under the terms, Immatics will receive an upfront payment of $120 million, along with research funding and milestone payments that could total more than $1.7 billion. Additionally, Immatics stands to earn royalties from future drug sales resulting from this collaboration.

This strategic alliance combines Moderna’s pioneering mRNA platform with Immatics’ expertise in immunology therapies, aiming to accelerate the creation of effective cancer-fighting vaccines.

Rose Loughlin, Moderna’s Senior Vice President of Research and Early Development, emphasized that the partnership is set to "fast-track the development of novel oncology treatments, bringing us closer to delivering significant benefits for patients facing critical unmet medical needs."

Toni Weinschenk, Chief Innovation Officer at Immatics, highlighted that the fusion of both companies’ assets "forms a powerful synergy with the potential to transform cancer patient outcomes."

The collaboration is pending customary U.S. antitrust approvals.

Following the announcement, Moderna’s shares dipped by 1.7% on Monday, reflecting a 41% decline year-to-date.

Discover the latest news and current events in Company News as of 16-09-2023. The article titled " Moderna and Immatics Join Forces in 2025 with $1.7 Billion Deal to Revolutionize Cancer Vaccines " provides you with the most relevant and reliable information in the Company News field. Each news piece is thoroughly analyzed to deliver valuable insights to our readers.

The information in " Moderna and Immatics Join Forces in 2025 with $1.7 Billion Deal to Revolutionize Cancer Vaccines " helps you make better-informed decisions within the Company News category. Our news articles are continuously updated and adhere to journalistic standards.